Catalyst Biosciences Inc. (CBIO) Has Tumbled To A 6-Month Low
Markets2018-06-18
0 Views
Catalyst Biosciences Inc. (CBIO) provided an update on its Phase 1/2 trial of CB 2679d/ISU304, for the treatment of severe hemophilia B, Monday morning.
Source: RTTNews
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
BREAKING NEWS: Herbal Works Inc. Searching for Brand Social Media Influencer and Social Media Brand Ambassador
